What is Anamorelin (non-peptide)?
An oral ghrelin-receptor agonist approved in Japan (Adlumiz) for cancer cachexia; it raises GH and IGF-1 and increases appetite and lean mass.
Anamorelin (non-peptide) in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?
11 registered trials · 13 indexed papers · 9 human / 1 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Anamorelin is described as a small-molecule oral ghrelin mimetic, in the same receptor class as ipamorelin and MK-677.
Mechanism (as described)
- It activates the ghrelin receptor (GHS-R1a), raising growth hormone and IGF-1 and stimulating appetite.
Evidence (as described)
- The phase 3 ROMANA 1 and 2 trials in lung-cancer cachexia reported increases in lean body mass but no improvement in handgrip strength (Temel et al., 2016). Japanese use is reviewed by Wakabayashi et al., 2023.
Status
Approved in Japan (2021) for cancer cachexia. Not FDA- or EMA-approved (EMA refused it in 2017).
Registered human trials (11)
Peer-reviewed studies (13)
More cited research
- Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placeb (None, human RCT)
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti (2024, animal)
Conditions researched
- Fat loss, obesity & body recomposition
- Fatigue & low energy (incl. midlife)
- Muscle gain, sarcopenia & building muscle after 40
- Osteoporosis and bone density
Related compounds
- Cyanocobalamin (Vitamin B12)
- Ghrelin
- L-Carnitine
- Leuprolide
- BNP (Nesiritide)
- Bimagrumab
- Carnosine
- IGF-1 LR3
- ACTH (Corticotropin)
- Cosyntropin
FAQ
What is Anamorelin (non-peptide)?
An oral ghrelin-receptor agonist approved in Japan (Adlumiz) for cancer cachexia; it raises GH and IGF-1 and increases appetite and lean mass.
How many registered human trials study Anamorelin (non-peptide)?
The PeptideWhiz trial index lists 11 registered trials for Anamorelin (non-peptide), the most recent from 2023.
How much published research exists on Anamorelin (non-peptide)?
The PeptideWhiz paper index links 13 PubMed papers to Anamorelin (non-peptide); by study type, 9 human and 1 animal studies.
Which conditions is Anamorelin (non-peptide) researched for?
Fat loss, obesity & body recomposition, Fatigue & low energy (incl. midlife), Muscle gain, sarcopenia & building muscle after 40, Osteoporosis and bone density.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).